Clinical trial
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban…
NCT00150241 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00150241 |
|---|---|
| Title | A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation |
| Official title | A Seven-Week Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Three Doses of CP-526,555 ( 0.3 mg QD, 1 mg QD, and 1 mg BID ) in Comparison With Zyban in Smoking Cessation |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smoking Cessation |
| Intervention type | Drug |
| Interventions | CP-526, 555 (varenicline) |
| Enrollment | 625 |
| Start date | Feb 1, 2000 |
| Completion | Jan 1, 2002 |
| First posted | Sep 8, 2005 |
| Last update posted | Oct 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: